|
|
| Line 7: |
Line 7: |
|
| |
|
| ==Prevention== | | ==Prevention== |
| ===AHA Scientific Statement on Kawasaki Disease===
| | Primary prevention for Kawasaki disease is not applicable. |
| ====Recommendations for Prevention of Thrombosis During the Acute Illness====
| |
| The [[American Heart Association|AHA]] Recommendations for the prevention of Thrombosis during the acute illness are:<ref name="McCrindleRowley2017">{{cite journal|last1=McCrindle|first1=Brian W.|last2=Rowley|first2=Anne H.|last3=Newburger|first3=Jane W.|last4=Burns|first4=Jane C.|last5=Bolger|first5=Anne F.|last6=Gewitz|first6=Michael|last7=Baker|first7=Annette L.|last8=Jackson|first8=Mary Anne|last9=Takahashi|first9=Masato|last10=Shah|first10=Pinak B.|last11=Kobayashi|first11=Tohru|last12=Wu|first12=Mei-Hwan|last13=Saji|first13=Tsutomu T.|last14=Pahl|first14=Elfriede|title=Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association|journal=Circulation|volume=135|issue=17|year=2017|pages=e927–e999|issn=0009-7322|doi=10.1161/CIR.0000000000000484}}</ref>
| |
| {| class="wikitable" style="width:80%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen" |<nowiki>"</nowiki>'''1.''' Low-dose ASA (3–5 mg·kg−¹·d−¹) should be administered to patients without evidence of coronary artery changes until 4 to 6 weeks after onset of illness.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| | bgcolor="LemonChiffon" |<nowiki>"</nowiki>'''1.''' For patients with rapidly expanding coronary artery aneurysms or a maximum Z score of ≥10, systemic anticoagulation with LMWH or warfarin (international normalized ratio target 2.0–3.0) in addition to low dose ASA is reasonable. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
| |
| |-
| |
| | bgcolor="LemonChiffon" |<nowiki>"</nowiki>'''1.''' For patients at increased risk of thrombosis, for example, with large or giant aneurysms (≥8 mm or Z score ≥10) and a recent history of coronary artery thrombosis, “triple therapy” with ASA, a second antiplatelet agent, and anticoagulation with warfarin or LMWH may be considered. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightCoral" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]]
| |
| |-
| |
| | bgcolor="LightCoral" |<nowiki>"</nowiki>'''1.''' Ibuprofen and other non steroidal anti-inflammatory drugs with known or potential involvement of cyclooxygenase pathway may be harmful in patients taking ASA for its antiplatelet effects. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| ====Recommendations for Risk Stratification of Coronary Artery Abnormalities====
| |
| | |
| {| class="wikitable" style="width:80%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| | bgcolor="LemonChiffon" |<nowiki>"</nowiki>'''1.''' It is reasonable to use echocardiographic coronary artery luminal dimensions converted to BSA-adjusted Z scores to determine risk stratification. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LemonChiffon" |<nowiki>"</nowiki>'''2.''' It is reasonable to incorporate both maximal and current coronary artery involvement in risk stratification. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LemonChiffon" |<nowiki>"</nowiki>'''3.''' It is reasonable to incorporate the presence of additional features other than coronary artery luminal dimensions into decisions regarding risk stratification. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| |
| |}
| |
|
| |
|
| ==References== | | ==References== |